Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.
Authors:
- Yoh DobashiYDYoh Dobashi
- Takayuki NojimaTNTakayuki Nojima
- Hiroyuki NakamuraHNHiroyuki Nakamura
- Norio YamamotoNYNorio Yamamoto
- Hiroyuki TsuchiyaHTHiroyuki Tsuchiya
- Hiroko IkedaHIHiroko Ikeda
- Seiko Sawada-KitamuraSSSeiko Sawada-Kitamura
- Takeru OyamaTOTakeru Oyama
- Akishi OoiAOAkishi Ooi
- 15 June 2013
- journal article
- research article
- Vol. 6 (7) , 1306-16
Abstract
The atypical lipomatous tumor (ALT)/well-differentiated liposarcoma (WDLS) and the de-differentiated liposarcoma (DDLS) represent the most common category of liposarcomas. ALT/WDLSs and DDLSs are often difficult to distinguish from other tumors with similar morphological characteristics. In this study, we investigated whether the detection of amplified or overexpressed murine double-minute 2 (MDM2) can be a useful diagnostic ancillary aid. We used fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) to detect MDM2 amplification and protein overexpression, respectively, in 49 WDLSs, 5 DDLSs, 23 myxoid liposarcomas, 25 benign lipomatous tumors, and 75 spindle and pleomorphic sarcomas. MDM2 amplification was detected in 48 of 49 WDLSs, 5 of 5 DDLSs, 2 of 9 malignant peripheral nerve sheath tumors, and 2 of 10 myxofibrosarcomas. We did not detect MDM2 amplification in any of the benign lipomatous tumors. FISH-mediated detection of MDM2 amplification was the most valuable diagnostic aid for ALT/WDLS, as determined by using the Fisher exact test to compare two different diagnoses of 19 biopsies. On the contrary, unequivocal nuclear overexpression of MDM2 was found in only 10 of 50 ALT/WDLSs. The sensitivity and specificity of MDM2 amplification in distinguishing a DDLS from spindle and pleomorphic sarcomas were 100% and 95%, respectively, while those of MDM2 overexpression were 100% and 87%, respectively. In conclusion, our results indicate that FISH-mediated detection of MDM2 amplification is the most useful adjunct in the diagnosis of both ALT/WDLS and DDLS. However, IHC-mediated detection of MDM2 protein is useful only for the diagnosis of DDLS.Keywords
This publication has 26 references indexed in Scilit:
- Gene amplification of ESR1 in breast cancers—fact or fiction? A fluorescence in situ hybridization and multiplex ligation‐dependent probe amplification studyThe Journal of Pathology, 2011
- MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the boneLaboratory Investigation, 2011
- Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?Laboratory Investigation, 2010
- Characterization of the 12q15 MDM2 and 12q13‐14 CDK4 amplicons and clinical correlations in osteosarcomaGenes, Chromosomes and Cancer, 2010
- Fluorescence In Situ Hybridization in the Diagnosis of Soft Tissue Neoplasms: A ReviewAdvances in Anatomic Pathology, 2009
- Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer TherapyAnnual Review of Pharmacology and Toxicology, 2009
- Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcomaLaboratory Investigation, 2009
- Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasmsLaboratory Investigation, 2008
- Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin‐3AInternational Journal of Cancer, 2007
- Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive InhibitorsChemistry & Biology, 2004